Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S ADR (NY: NVO )

105.06 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
65 66 Next >
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
The carnivore diet is back in the spotlight as people seek GLP-1 alternatives; here are two meat stocks that are moving higher on this trend 
Via MarketBeat
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds. 
Via The Motley Fool
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
The battle for the obesity therapies market is escalating. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets
Eli Lilly: BofA Securities rates it a top pick in Biopharma, with a YTD performance of +29%. Analysts highlight undervalued opportunities in heart disease, sleep apnea, and liver disease. Price target... 
Via Benzinga
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable. 
Via The Motley Fool
Ozempic, Wegovy Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns
The World Health Organization has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone. 
Via Benzinga
5 Investors Betting Big on Weight Watchers (WW) Stock as Oprah Backs Out
WW stock is falling lower after its earnings, adding that Oprah Winfrey would step down from the board of directors. 
Via InvestorPlace
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
These stocks meet many of the criteria long-term investors look for. 
Via The Motley Fool
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week. 
Via The Motley Fool
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
Why Is Vivani Medical (VANI) Stock Up 300% Today?
With Vivani Medical introducing pre-clinical efficacy data for its weight-loss solution, VANI stock soared on the broader implications. 
Via InvestorPlace
Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say
Viking Therapeutics achieves significant weight loss in the VENTURE trial, outperforming rivals in body weight reductions. 
Via Benzinga
What Would George Soros Do? 7 Stocks the Billionaire’s Fund Bought & Sold in Q4
Dive into the insightful analysis on George Soros stocks in Q4 highlighting the foresight of an investing titan. 
Via InvestorPlace
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D... 
Via Benzinga
Miracle Or Myth? Survey Shows Americans Doubt Ozempic, Wegovy's Weight Loss Claims
The survey, conducted from Feb. 7 to Feb. 11, found that only 35% believe these drugs will somewhat reduce obesity, while 33% think they will have little to no impact. 
Via Benzinga
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo... 
Via Benzinga
Why Novo Nordisk and Eli Lilly Stocks Slipped Today
A competitor to Wegovy and Zepbound might appear on pharmacy shelves before long. 
Via The Motley Fool
Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results
Eli Lilly and Novo Nordisk fell modestly. 
Via Investor's Business Daily
Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now
The seven companies discussed here have every chance of becoming the next trillion dollar stocks for investors. 
Via InvestorPlace
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
These 2 carnivore dining stocks gaining on the Ozempic craze
Ozempic and GLP-1 parallel the artificial intelligence (AI) mania, but it has also propelled "carnivore" restaurants like the two we feature here. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
This Warren Buffett Stock Is On The Cusp Of Joining The $1 Trillion Club
Berkshire Hathaway is just below a $1 trillion market cap. 
Via Investor's Business Daily
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.